More studies needed for pediatric doses

All the debate over the safety of kids' drugs lately--from over-the-counter cold meds to Tamiflu and Advair to antidepressants--stems from a single cause, according to a Washington Post think piece. Most drugs given to kids were never tested on kids.

For years, conducting clinical trials on kids was considered unethical. Drug makers and regulators figured kids' doses could simply be scaled down from adult levels. Plus, kid-oriented research was expensive and difficult.

Now that's changing, but not fast enough for some experts. Children aren't a big enough share of the market to prompt a wholesale overhaul, some say. Many drugs that need to be studied in kids are already off patent, so drug companies have no incentive to do it. Of the 50 old drugs considered "high-priority" for pediatric trials, studies are beginning on only 14, and these are in the preliminary phases.

Meanwhile, some recent legislation and special programs are using the carrot-plus-stick approach to pediatric trials funded by drugmakers--and so, as the FDA put it, we're learning how much we don't know. For instance, a fifth of the adult drugs tested in kids simply didn't work. Another third caused unexpected side effects, some potentially deadly. "That's what keeps me up at night," one pediatrics prof said. Indeed.

- read the Washington Post report

Related Articles:
FDA does a triple-take on Tamiflu. Report
FDA reconsiders Glaxo asthma meds. Report
Wyeth pulls cold remedies for kids. Report
FDA panel: No cold meds for under-6 kids. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.